Trial Profile
An Open-label, Randomised, Active Controlled Multi-center Phase II Dose Finding Study to Evaluate the Ability of PA21 to Lower Serum Phosphate Levels and the Tolerability in Patients With Chronic Kidney Disease on Maintenance Hemodialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Sevelamer
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Vifor
- 31 Jul 2014 New trial record
- 27 Jun 2014 Results published in a Vifor Pharma media release.
- 27 Jun 2014 Primary endpoint 'Change From Baseline in Serum-phosphate Levels at the End of Treatment' has been met according to a Vifor Pharma media release.